



iTrack™ Canaloplasty to be Featured at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

California, USA, April 23, 2023 – Nova Eye Medical Limited, a medical technology company committed to advanced ophthalmic treatment technologies and devices, is pleased to announce that the Company's proprietary iTrack™ canaloplasty technology will be featured during the official scientific program of the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, taking place on April 23 - 27, 2023, in New Orleans, Louisiana.

Poster presentation:

Michael Yipeng Chen, MD; Ahmed Aref, MD

Efficacy and Safety Profile of Ab-Interno Canaloplasty Performed With and Without GATT – 12 Month Outcomes

Session: Glaucoma Surgery and Wound Healing

Date: Wednesday, April 26, 2023

Time: 10:30 AM - 12:15 AM

ABOUT NOVA EYE MEDICAL

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons in more than 100 countries globally, these technologies include iTrack™, a consumable surgical device for the treatment of glaucoma. The Company also manufactures and sells the proprietary Molteno3® glaucoma drainage device for the treatment of severe or complex glaucoma. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by sales offices in Adelaide, Australia and Berlin, Germany, and a global network of more than 50 distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.



For additional information about Nova Eye Medical and its technologies, please visit:

www.nova-eye.com

ABOUT CANALOPLASTY

First introduced in 2008, canaloplasty is a surgical treatment for glaucoma that targets the main sites of outflow resistance in the conventional outflow pathway: the trabecular meshwork, Schlemm's canal, and the distal collector channels. Based on the same principles as angioplasty, a flexible microcatheter is cannulated 360 degrees around Schlemm's canal during the procedure to manually break and remove blockages. Next, viscoelastic fluid is injected into Schlemm's canal as the microcatheter is withdrawn to dilate the distal outflow system and to improve the function of the trabecular meshwork.

ABOUT THE iTRACK™ PORTFOLIO

Nova Eye Medical (formerly iScience Interventional) pioneered the canaloplasty market with the launch of the world's first canaloplasty device, *iTrack*™, in 2008. Since then, more than 120,000 canaloplasty procedures have been performed with the *iTrack*™ canaloplasty device, cementing its role in the treatment of glaucoma both as a standalone procedure and in combination with cataract surgery.

The iTrack™ canaloplasty microcatheter has been cleared for the indication of fluid infusion and aspiration during surgery, and for catheterization and viscodilation of Schlemm's canal to reduce intraocular pressure in adult patients with open-angle glaucoma. The iTrack™ canaloplasty microcatheter is currently not 510(k) cleared for use with the ab-interno technique in the United States.

For additional information about *iTrack*™, including safety information, please visit:

www.glaucoma-iTrack.com